Biotechnology firms AstraZeneca and Amgen have signed an agreement to jointly develop and commercialise five monoclonal antibodies to deliver treatments across multiple indications in inflammatory diseases.
The respiratory, inflammation and asthma development expertise of AstraZeneca’s biologics unit MedImmune will help Amgen to expand its portfolio.
As per the terms of the deal, AstraZeneca will make a one-time $50m upfront payment and the companies will share both costs and profits.
Amgen will book sales globally and will retain a low single-digit royalty for brodalumab and a mid single-digit royalty for the rest of the portfolio after which the companies will share profits equally.
For brodalumab, Amgen will promote in dermatology indications in the US and Canada, and in rheumatology indications in US, Canada and Europe. AstraZeneca will promote in respiratory and, initially, in dermatology indications of brodalumab across all territories outside of the US, Canada and those markets where Amgen has existing partnerships.
David Brennan, CEO of AstraZeneca, said: "We are delighted to join forces with Amgen in developing and commercialising these novel clinical-stage assets that add value to our pipeline and build on our expertise in biologics. This creative collaboration will make the most of both companies’ respective capabilities, including AstraZeneca’s extensive global reach, to help bring these potentially innovative treatment options for a variety of respiratory and inflammatory diseases to patients around the world."
Kevin Sharer, chairman and CEO of Amgen, said: "We are very excited at the prospect of collaborating with a well-respected organisation like AstraZeneca to advance our inflammation pipeline.
"We believe this collaboration has the potential to bring more therapies to patients sooner, across more geographic areas. We are impressed with AstraZeneca's extensive experience in developing and launching products in the respiratory and gastroenterology areas, and believe this collaboration is an opportunity to work with a partner that has leading regulatory and commercial expertise in inflammation indications."